Compare Novartis AG (NVS) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Xcel Energy Inc — how do they compare? Novartis AG trades at $152.66 (market cap $295.37B), while Xcel Energy Inc trades at $78.02 (market cap $48.51B). The key difference: Novartis AG is far larger — about 6.1× Xcel Energy Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | XEL | |
|---|---|---|
Market Cap | $295.37B | $48.51B |
Sector | Health | Utilities |
52-Week High | $168.62 | $83.91 |
52-Week Low | $119.31 | $71.75 |
Enterprise Value | $336.69B | $86.82B |
Dividend Yield | 3.07% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Xcel Energy (XEL) trades at $76.87, down 1.54% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, and maintains a solid dividend. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%, while analyst consensus is bullish with a $93.80 price target.
The outlook is supported by earnings growth and a $60 billion capital investment plan, but risks include regulatory pushback and high debt levels. The stock offers a stable investment opportunity with growth potential from infrastructure spending, though affordability concerns and interest rate sensitivity pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
